News

An avocado a day could help redistribute belly fat in women toward a healthier profile, according to a new study.

Researchers from the University of Oxford and the Ludwig Institute for Cancer Research are harnessing the viral vector technology used to create the Oxford–AstraZeneca vaccine against SARS-CoV-2 to develop a vaccine to treat cancer.

A higher intake of flavonoid-rich foods (present in berries, apples, tea, red wine) is associated with a clinically relevant reduction in blood pressure levels, an association that is partially explained by characteristics of the gut microbiome.

Researchers have developed a method to convert captured carbon dioxide into methane, the primary component of natural gas, in an effort to make carbon capture more affordable.

The free-living planarian Schmidtea mediterranea is capable of regenerating an entire body from a tiny portion of tissue. How it accomplishes this has largely been a mystery. In a recent study, researchers show that whole-body regeneration involves transcriptional changes in cells from all three germ layers of the body, and that tissue from areas distant from, as well as nearby to the site of injury, contribute to the process of regeneration.

Right now, in your body, lurk thousands of cells with DNA mistakes that could cause cancer. Yet only in rare instances do these DNA mistakes, called genetic mutations, lead to a full-blown cancer. Why?

Without genetic material, how did the earliest cells divide? A new theoretical model suggests that heat might have been the driving force. The study is published in Biophysical Journal.

A study of patient experience has shown that the use of next-generation brain implants for treating refractory epilepsy does not induce changes to patients’ personalities or self-perceptions.

A new computational approach may predict how individual patients are likely to respond to vaccines. In the future, it could lead to new design principles for vaccines that take an individual’s personalized characteristics into account.

Vaccinations against human papillomavirus (HPV) are expected to yield significant reductions in the rates of throat and mouth cancers in the U.S., but will not do so until after 2045, according to a new modeling study.